HR-Positive Breast Cancer: Growing Demand for ctDNA Testing and Implementation Challenges

This segment explores increasing interest from both patients and clinicians in ctDNA testing and emerging targeted therapies in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky highlights growing awareness driven by clinical data and public exposure, prompting more patients to inquire about ESR1 testing and potential treatment options.

Dr. Lisa Raff notes that both physicians and patients are actively engaging with new data presented at major oncology meetings, often leading to questions about early adoption of emerging therapies. However, she emphasizes the challenge of balancing enthusiasm with the need to wait for regulatory approval and more mature evidence.

Ms. Lori Brisbin adds that testing laboratories and patient-driven inquiries are increasingly influencing clinical workflows. She highlights variability in testing approaches and the lack of standardized guidance on testing cadence and interpretation. Overall, this segment underscores the growing demand for molecular testing alongside the operational and clinical challenges of implementation.